Bioventus Inc. (NASDAQ:BVS) Receives Average Recommendation of “Buy” from Brokerages

Shares of Bioventus Inc. (NASDAQ:BVS) have been assigned a consensus recommendation of “Buy” from the four ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $14.00.

BVS has been the subject of a number of recent research reports. Weiss Ratings restated a “hold (c-)” rating on shares of Bioventus in a research note on Monday, December 29th. Barrington Research raised their price objective on shares of Bioventus from $13.00 to $14.00 and gave the company an “outperform” rating in a research note on Friday, March 6th. Craig Hallum lifted their price objective on shares of Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday, March 6th. Finally, Cantor Fitzgerald raised shares of Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th.

Bioventus Trading Down 0.8%

Shares of Bioventus stock opened at $8.92 on Thursday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.19 and a current ratio of 1.70. Bioventus has a 52 week low of $5.81 and a 52 week high of $10.13. The stock has a 50 day moving average price of $8.33 and a two-hundred day moving average price of $7.58. The stock has a market capitalization of $741.70 million, a PE ratio of 27.03 and a beta of 0.78.

Bioventus (NASDAQ:BVS) last issued its earnings results on Thursday, March 5th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.02. Bioventus had a return on equity of 28.88% and a net margin of 4.00%.The company had revenue of $157.90 million for the quarter. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.

Insider Transactions at Bioventus

In other Bioventus news, Director Michelle Mcmurry-Heath sold 12,000 shares of Bioventus stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total transaction of $105,480.00. Following the completion of the transaction, the director owned 44,997 shares in the company, valued at approximately $395,523.63. The trade was a 21.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 33.00% of the company’s stock.

Institutional Trading of Bioventus

Institutional investors and hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd boosted its position in shares of Bioventus by 17,156.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after buying an additional 5,490 shares during the last quarter. PharVision Advisers LLC bought a new stake in Bioventus during the second quarter worth $67,000. Covestor Ltd raised its position in Bioventus by 28.0% in the 3rd quarter. Covestor Ltd now owns 9,951 shares of the company’s stock valued at $67,000 after buying an additional 2,176 shares during the last quarter. Fox Run Management L.L.C. bought a new position in Bioventus during the 2nd quarter valued at $72,000. Finally, HB Wealth Management LLC bought a new position in Bioventus during the 3rd quarter valued at $72,000. 62.94% of the stock is owned by hedge funds and other institutional investors.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.